Correspondence

Does dual vs. triple antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation lower the risk of bleeding at the cost of increased risk of ischemic events?☆

Kartik Gupta a,1, Shane P. Prejean a,1, Muthiah Vaduganathan b,c, Harsh Golwala d, Thomas Evan Watts a, Sudeep R. Aryal d, Gregory von Mering a, Oscar Julian Booker a, Mustafa I. Ahmed a, Navkaranbir S. Bajaj a,e,f,*

a Division of Cardiovascular Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
b Brigham and Women's Hospital Heart and Vascular Center, Boston, MA, USA
c Harvard Medical School, Boston, MA, USA
d Division of Molecular Imaging and Therapeutics, Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, USA
e Section of Cardiology, Birmingham Veterans Affairs Medical Center, Birmingham, AL, USA
f Division of Molecular Imaging and Therapeutics, Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, USA

ARTICLE INFO

Article history:
Received 6 May 2019
Received in revised form 9 July 2019
Accepted 10 July 2019
Available online 17 July 2019

Keywords:
Antithrombotic therapy
Atrial fibrillation
Bleeding
Percutaneous coronary intervention
Stent thrombosis

A significant proportion of patients with atrial fibrillation (AF) undergo percutaneous coronary intervention (PCI) [1]. Use of triple antithrombotic therapy (TAT) in patients with AF undergoing PCI contributes to increased bleeding risk [2]. The optimum choice of antithrombotic therapy in patients with AF undergoing PCI is unclear, given the need for anticoagulation to prevent stroke, and antiplatelet therapy to prevent myocardial infarction (MI) and stent thrombosis [3].

Dual antithrombotic therapy (DAT) in these patients reduces bleeding events in randomized controlled trials (RCTs) [4–8]. Some of these RCTs [7,8] raise a concern that this benefit may occur at the expense of an increased risk of ischemic events [1,9], however, none of these RCTs were powered for ischemic events. We, therefore, performed meta-analyses to evaluate the risk of ischemic and bleeding events with DAT vs. TAT using data from the RCTs [4–8]. We followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Primary efficacy endpoint was composite ischemic events (composite of MI, stent thrombosis and ischemic stroke). Definitions of MI and ischemic stroke were comparable across all trials. Stent thrombosis was reported as definite in 3 RCTs [4,5,7], definite or probable in 1 RCT [8] and trial defined stent thrombosis events were used for PIONEER AF-PCI [6]. Primary safety endpoint was defined as major or minor bleeding according to the Thrombolysis in Myocardial Infarction (TIMI) criteria. Secondary endpoints were TIMI major bleeding, intracranial bleeding, all-cause and cardiovascular (CV) mortality, and individual components of ischemic events. The outcomes were reported at 6 months [7,8], 9 months [5], or 12 months [4,6].

Random effects modeling was used to estimate the summary risk ratios (RRs). A two-sided p < 0.05 was considered statistically significant. Continuity correction was applied in case of zero events. We estimated the power of our pooled analysis to detect difference in ischemic events. We also estimated sample size of a future trial/meta-analysis with 80% power and a two-sided α = 0.05 to detect the observed effect estimates for ischemic events in our pooled analysis.

Pooled number needed to harm (NNH) to cause one ischemic event and number needed to treat (NNT) to prevent one TIMI major or minor bleeding were calculated using meta-analysis of risk differences [10]. Additionally, the number needed to cause other secondary endpoint (s) were calculated. All analyses were performed using the STATA V15.0 (College Station, TX, USA) statistical software.

Five RCTs with 9931 patients met our eligibility criteria. There was an increased risk of ischemic events with DAT vs. TAT but this did not reach statistical significance (5.4% vs. 4.4%, RR: 1.2, p = 0.423) (Table 1 and Fig. 1). There was no difference in the risk of myocardial infarction or ischemic stroke (p > 0.1 for both) (Table 1). The risk of stent thrombosis was modestly increased with DAT as compared with TAT (p = 0.088) (Table 1). Given the lack of statistical significance for ischemic events, we performed a post-priori power calculation. The power of our meta-

* All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.
☆ Corresponding author at: The University of Alabama at Birmingham, LHRB 336, 701 19th St S, Birmingham 35233, AL, USA, E-mail address: nbajaj@uabmc.edu (N.S. Bajaj).
1 Co-primary authors.
The subsequently published AUGUSTUS trial [8] suggested that the risk of major or minor bleeding with DAT vs. TAT (4% vs. 7.7%, RR: 0.52, p < 0.001) (Table 1). The major bleeding events were lower in DAT as compared with TAT whereas no difference was seen in the risk of intracranial bleeding, all-cause mortality or cardiovascular mortality. The estimated NNT to prevent one major or minor bleeding event was 27, and whereas the NNH to cause one ischemic event was 200 (Fig. 1).

Our meta-analysis confirms that among patients with AF undergoing PCI, DAT reduced the risk of bleeding as compared with TAT. We further observed a numerical excess in the risk of ischemic events in the DAT arm that did not reach statistical significance. The meta-analysis at the current sample size is adequately powered to detect the observed difference. The NNH to cause one ischemic event with DAT was 7 times higher than the NNT to prevent one TIMI major or minor bleeding with TAT.

A previously published meta-analysis [2] of 4 RCTs reported a similar 47% reduction in the risk of major or minor bleeding with DAT vs. TAT, without a significant difference in the risk of MI or stent thrombosis. The subsequently published AUGUSTUS trial [8] suggested that the risk of stent thrombosis with DAT was modestly increased (0.9% and 0.5% with DAT and TAT, respectively) which was not statistically significant [8]. Interestingly, the two trials which reported a higher risk of MI and stent thrombosis with DAT (RE-DUAL PCI and AUGUSTUS) also had a higher prevalence of diabetes and ACS as compared with the other three. Previous studies have identified these risk factors as important predictors of ischemic events after PCI [11].

The risk of MI and stent thrombosis after PCI also varies according to the target vessel re-vascularized, the type of occlusion (acute vs. chronic), type of stent, coronary anatomy, and re-intervention status; a single antithrombotic therapy approach is hence unlikely to be the solution for all patients. Certain patients with a higher risk of ischemic events and lower bleeding risks may still benefit from at least a short period of TAT. Further, with the increasing use of non-vitamin K antagonist oral anticoagulants and broader application of bleeding-reduction strategies, it is expected that the relative risk of bleeding with TAT may decrease in clinical practice. Future studies (RT-AF; NCT02334254; SAFEA, UMIN000015923; ENTRUST-AF PCI, NCT02866175) and meta-analyses will be required to reliably estimate the increased risk of ischemic events with DAT vs. TAT.

Heterogeneity in the indication for anticoagulation, PCI, revascularization strategy, variable follow-up, and lack of patient level data limits the understanding of the ideal antithrombotic strategy and the ideal candidate for TAT in patients with AF undergoing PCI. It is important to recognize that these trials and our meta-analysis were not adequately powered to estimate the risk of ischemic events.

DAT decreases the risk of major or minor bleeding with a possible increase in the risk ischemic events among patients with AF undergoing PCI.

Table 1
Risk of outcomes with DAT vs. TAT.

| Outcome | Events in DAT (%) | Events in TAT (%) | RR (95% CI) | p-Value |
|---------|------------------|------------------|-------------|----------|
| TIMI major or minor bleeding | 4 | 7.7 | 0.53 (0.44-0.63) | <0.001 |
| TIMI major bleeding | 1.7 | 3 | 0.55 (0.43-0.72) | <0.001 |
| Intracranial bleed | 0.4 | 0.6 | 0.71 (0.29-1.76) | 0.460 |
| Ischemic events* | 5.4 | 4.4 | 1.12 (0.85-1.47) | 0.423 |
| MI | 3.3 | 2.9 | 1.17 (0.94-1.47) | 0.164 |
| Stent thrombosis | 0.9 | 0.6 | 1.52 (0.94-2.45) | 0.088 |
| Stroke | 1.1 | 1 | 1.02 (0.62-1.60) | 0.293 |
| MI/stent thrombosis | 4.4 | 3.4 | 0.91 (0.70-1.19) | 0.493 |
| Mortality | 3.7 | 3.8 | 0.93 (0.57-1.50) | 0.753 |
| Cardiovascular mortality | 2.2 | 2.2 | 2.45 (0.088) | 0.001 |

* Ischemic events defined as a composite of myocardial infarction, stent thrombosis and ischemic stroke. CI: confidence interval, DAT: dual antithrombotic therapy; MI: myocardial infarction, RR: Risk Ratio, TAT: triple antithrombotic therapy, TIMI: thrombolysis in myocardial infarction.

Fig. 1. Forest Plot comparing DAT versus TAT for primary efficacy endpoint (ischemic events) and primary safety endpoint (TIMI major or minor bleeding) (Panel A). The estimates in the right columns are RRs with 95% CI. In the case of zero events, continuity correction was applied. The number needed to treat (NNT) to prevent one major or minor bleed and number needed to harm (NNH) to cause one ischemic event for individual trials and summary estimates. The size of the bubbles is proportional to the number of patients. More efficacious implies higher NNH to cause one ischemic event; safer implies lower NNT to prevent one bleeding event (Panel B).
PCI. Choice of DAT vs. TAT should continue to be individualized based on the patient's clinical risk, coronary anatomy, and PCI factors.

**Declaration of Competing Interest**

Dr. Vaduganathan is supported by the KL2/Catalyst Medical Research Investigator Training award from Harvard Catalyst (NIH/NCATS Award UL1TR002541), serves on advisory boards for Amgen, AstraZeneca, Bayer AG, and Baxter Healthcare, and participates on clinical endpoint committees for studies sponsored by Novartis and the NIH. Dr. Mering serves on the advisory board of Boston Scientific. Dr. Ahmed receives honoraria for teaching activities from Abbott and Medtronic and is an investigator for the SUMMIT trial [ClinicalTrials.gov Identifier: NCT03433274]. The other authors declare no competing interests.

**Acknowledgment of grant support**

Dr. Bajaj is supported by the American College of Cardiology Presidential Career Development Award, the Walter B. Frommeyer, Jr., Fellowship in Investigative Medicine, and National Center for Advancing Translational Research of the National Institutes of Health under award number UL1TR001417.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the American College of Cardiology or National Institutes of Health.

**References**

[1] S.R. Mehta, Refining antithrombotic therapy for atrial fibrillation and acute coronary syndromes or PCI, N. Engl. J. Med. 380 (2019) 1580–1581.

[2] H.B. Golwala, C.P. Cannon, P.G. Steg, G. Doros, A. Qamar, S.G. Ellis, J. Oldgren, J.M. Ten Berg, T. Kimura, S.H. Hohnloser, G.Y.H. Lip, D.L. Bhatt, Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials, Eur. Heart J. 39 (19) (2018) 1728–1735a.

[3] M.L. Hansen, R. Sorensen, M.T. Clausen, M.L. Fog-Petersen, J. Raunso, N. Gaddboll, G.H. Giliason, F. Folke, S.S. Andersen, T.K. Schramm, S.Z. Abildstrom, H.E. Poulsen, L. Kofer, C. Torp-Pedersen, Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation, Arch. Intern. Med. (2010) 1701433–1701441.

[4] W.J.M. Dewilde, T. Oribans, F.W.A. Verheugt, J.C. Kelder, B.J.G.L. De Smet, J.-P. Herrman, T. Adriaenssens, M. Vrolix, A.A.C.M. Heestermans, M.M. Vis, J.G.P. Tijsen, A.W. van’t Hof, J.M. ten Berg, Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial, Lancet 381 (2013) 1107–1115.

[5] K.A. Fiedler, M. Maeng, J. Mehillsi, S. Schulz-Schüpke, R.A. Byrne, D. Sibbing, P. Hoppmann, S. Schneider, M. Fuxaro, I. Ott, S.D. Kristensen, T. Ibrahim, S. Massberg, H. Schunkert, K.-L. Laugwitz, A. Kastrati, N. Saraff, Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial, J. Am. Coll. Cardiol. (2015) 651619–651629.

[6] T.M. Gibson, R. Mehran, C. Bode, J. Halperin, F.W. Verheugt, P. Wildgoose, M. Birmingham, J. Janus, P. Burton, M. van Eickels, S. Korjlan, Y. Daaboul, G.Y.H. Lip, M. Cohen, S. Husted, E.D. Peterson, K.A. Fox, Prevention of bleeding in patients with atrial fibrillation undergoing PCI, N. Engl. J. Med. 375 (2016) 2423–2434.

[7] C.P. Cannon, D.L. Bhatt, J. Oldgren, G.Y.H. Lip, S.G. Ellis, T. Kimura, M. Maeng, B. Merkely, U. Zeymer, S. Gropper, M. Nordaby, E. Kleine, R. Harper, J. Manapie, J.L. Januzzi, J.M. ten Berg, P.G. Steg, S.H. Hohnloser, Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation, N. Engl. J. Med. 377 (2017) 1513–1524.

[8] R.D. Lopes, G. Heizer, A.N. Vora, T. Massaro, R. Mehran, S.G. Goodman, S. Stone, A. Colombo, A. Chieffo, A.S. Kini, B. Witzenbichler, G. Weisz, P.G. Steg, A. Kastrati, Omission of aspirin after ACS or stenting in patients with oral anticoagulation - why have the goalposts moved? EuroIntervention. (2019) 14e1793–e5.

[9] R.A. Byrne, R. Colleran, A. Kastrati, Omission of aspirin after ACS or stenting in patients with oral anticoagulation - why have the goalposts moved? EuroIntervention. (2019) 14e1793–e5.

[10] N.S. Bajaj, M. Vaduganathan, A. Qamar, K. Gupta, A. Gupta, H. Golwala, J. Butler, S.Z. Abildstrom, M.R. Mehra, Extended prophylaxis for venous thromboembolism after hospitalization for medical illness: a trial sequential and cumulative meta-analysis, PloS Med. 16 (2019), e1002797.